BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma
Shots:
- The approval is based on the P-III CheckMate -274 trial evaluating Opdivo (240mg- IV- q2w- for ~1 yrs.) vs PBO in a ratio (1:1) in 709 patients with UC who are at high risk of recurrence after undergoing radical resection
- The results showed a 30% reduction in the risk of disease recurrence or death- m-DFS (20.8 vs 10.8mos.) in the ITT population. Additionally- m-DFS (not reached vs 8.4mos.) among patients whose tumors express PD-L1 ≥1% with a 45% reduction in risk of disease recurrence or death
- The application was approved under the FDA’s RTOR pilot program. The results further support the conversion of Opdivo’s accelerated approval to regular approval
Ref: BMS | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com